Endocrine Therapy

Incidence of venous thromboembolism remained high among patients with cancer even as the treatment landscape has evolved over the past 16 years, according to data published in JAMA Network Open.

CHICAGO — The addition of ribociclib to endocrine therapy improved invasive DFS vs. endocrine therapy alone in patients with hormone receptor-positive, HER2-negative early-stage breast cancer.

Postmenopausal women with early-stage breast cancer adapted successfully to the disease and endocrine therapy whether it was tamoxifen or aromatase inhibitor, researchers reported in Menopause.

Among patients with breast cancer in China, those who underwent adjuvant endocrine therapy had more prevalent and more severe menopausal symptoms, according to data published in Menopause.

High allostatic load indicating lifelong stress was linked to a 106% increased risk for cancer-associated death among young Black individuals and a 95% increased risk among young white individuals, according to a recent study.

SAN ANTONIO — Young women with early hormone receptor-positive breast cancer who temporarily stopped endocrine therapy to attempt pregnancy experienced similar short-term recurrence risk as those who did not stop, according to study results.

SAN ANTONIO — A genomic assay identified risk for distant recurrence among certain premenopausal women with hormone receptor-positive, early-stage breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Endocrine therapies have revolutionized the field of breast cancer, with significant improvements in survival outcomes among patients with hormone receptor-positive disease.

Adjuvant palbociclib combined with endocrine therapy failed to extend invasive DFS compared with endocrine therapy alone among patients with stage IIA hormone receptor-positive, HER2-negative breast cancer, according to study results.

Breast Cancer Awareness Month is observed every October.